Abstract
This week, the London-based Society of Chemical Industry will present its annual Centenary Medal to a 40-yearold serial biotechnology entrepreneur. Christopher T. Evans, chairman of Merlin Ventures Ltd., a venture-capital company specializing in biotechnology start-ups, is one of the darlings of the London financial community, one of those rare people who has struck gold— and kept it—in biotechnology. He has been involved in founding a variety of bioscience companies. Among his biotech ventures: • Enzymatix, an enzyme chemistry specialty firm he founded when he was 28; some of its businesses were sold off in a variety of deals, others formed the basis of subsequently founded companies. • Celcis International, a rapid-methods diagnostics company; it was launched on the London stock market in 1993. • Chiroscience, a chiral chemistry pharmaceutical specialty producer originally called Chiros; launched on the London stock market in 1994. • Cerebrus, a neuroscience research company; to be launched on the Lon...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
